Abstract
To the Editor: In their report on a trial of low-dose colchicine (LoDoCo2) in patients with chronic coronary disease, Nidorf et al. (Nov. 5 issue)1 found that those who received colchicine had a 31% lower risk of adverse cardiovascular events than those who received placebo (hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83). This finding supports the role of inflammation as a key mediator in the development of cardiovascular disease. In one prespecified subgroup analysis, we noticed an interesting interaction showing a greater treatment effect among the patients in Australia than among those in the Netherlands (hazard ratios .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
